For Immediate Release

2014.11.06

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Joji Nakayama, Representative Director, President and CEO
(Code no.: 4568, First Section, Tokyo Stock Exchange)
Please address inquiries to Noriaki Ishida Corporate Officer,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126
http://www.daiichisankyo.com

20141105_Correction management presentation docs

TOKYO, Japan (November 5, 2014) - With regard to the above, we wish to inform that there were typo errors in the document, which was filed on November 4, 2014 at 11:30, as follows.

Correction

(1)     Page20  Progress in R&D pipeline  CL-108  region

Page23  Major R&D Pipeline  CL-108 region

Before: US/EU

After       :  US

(2)     Page20  Progress in R&D pipeline DS-6051  region

Page23  Major R&D Pipeline  DS-6051 region

Before:  JP

After       : US

(3)     Page21  CL-108: Hydrocodone combination the second line

Before     : Exclusive license for commercialization in US/EU

After       : Exclusive license for commercialization in US

More information regarding Daiichi Sankyo's FY2014 Q2 financial results can be found at the following link:

http://www.daiichisankyo.com/media_investors/investor_relations/quarterly_results/index.html

distributed by